Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. BET bromodomain inhibitors, which have shown efficacy in several models of cancer have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Shu, Shaokun, Lin, Charles Y., He, Housheng Hansen, Witwicki, Robert M., Tabassum, Doris P., Roberts, Justin M., Janiszewska, Michalina, Jin Huh, Sung, Liang, Yi, Ryan, Jeremy, Doherty, Ernest, Mohammed, Hisham, Guo, Hao, Stover, Daniel G., Ekram, Muhammad B., Peluffo, Guillermo, Brown, Jonathan, D’Santos, Clive, Krop, Ian E., Dillon, Deborah, McKeown, Michael, Ott, Christopher, Qi, Jun, Ni, Min, Rao, Prakash K., Duarte, Melissa, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Anders, Lars, Young, Richard A., Winer, Eric P., Letai, Antony, Barry, William T., Carroll, Jason S., Long, Henry W., Brown, Myles, Liu, X. Shirley, Meyer, Clifford A., Polyak, Kornelia, Bradner, James
अन्य लेखक: Broad Institute of MIT and Harvard
स्वरूप: लेख
भाषा:en_US
प्रकाशित: Nature Publishing Group 2017
ऑनलाइन पहुंच:http://hdl.handle.net/1721.1/109131

इंटरनेट

http://hdl.handle.net/1721.1/109131

समान संसाधन